< back to release list

Raze Therapeutics Announces Addition of Julian Adams, PhD,
George Q. Daley, MD, PhD, and Karen Vousden, PhD, to Scientific Advisory Board

Members Expand Company’s Expertise in Cancer Metabolism Drug Discovery and Development

Cambridge, MA, January 7, 2015 – CAMBRIDGE, Mass., Jan. 7, 2015— Raze Therapeutics, a leading next generation cancer metabolism company, announced today the expansion of its Scientific Advisory Board (SAB) with the addition of three leaders in oncology drug discovery and development.

New to the Raze SAB are Julian Adams, PhD, President of Research and Development at Infinity Pharmaceuticals, Inc.; George Q. Daley, MD, PhD, the Samuel E. Lux IV Professor of Hematology/Oncology and Director of the Stem Cell Transplantation Program at Children’s Hospital Boston; and Karen Vousden, PhD, Director of the Cancer Research UK Beatson Institute.

They join scientific founders and current SAB members Vamsi Mootha, MD, of Massachusetts General Hospital, Joshua Rabinowitz, MD, PhD, of Princeton, and David Sabatini, MD, PhD, of the Whitehead Institute; as well as current SAB members Keith Flaherty, MD, Director of the Henri and Belinda Termeer Center for Targeted Therapies at the Massachusetts General Cancer Center, and Michael Gilman, PhD, Chief Executive Officer of Padlock Therapeutics and an Atlas Venture Entrepreneur-in-Residence.
“Raze is translating breakthrough insights by our founders in cancer one-carbon metabolism to create novel therapeutic programs for patients with solid and hematologic malignancies,” said Jason Rhodes, acting Chief Executive Officer of Raze. “We are very pleased to have the support of our exceptional scientific advisory board.”

At Infinity, Julian Adams is responsible for the company’s drug discovery, preclinical research, clinical development, and regulatory affairs activities. Prior to joining Infinity in 2003, Dr. Adams was the Senior Vice President of Drug Discovery and Development at Millennium Pharmaceuticals, where he had global responsibility for multiple drug discovery programs, including the successful discovery and development of bortezomib (Velcade®), a proteasome inhibitor for cancer therapy.
In addition to his role at Children’s Hospital Boston, George Q. Daley is a Professor of Biological Chemistry and Molecular Pharmacology and Pediatrics at Harvard Medical School, an investigator of the Howard Hughes Medical Institute, and a founder and adviser to numerous successful biotechnology start-ups. Dr. Daley’s past work on the role of BCR/ABL in chronic myeloid leukemia paved the way for the development of imatinib (Gleevec®). His current research exploits mouse and human disease models to identify mechanisms that underlie cancer and hematological diseases.

Karen Vousden has served as Director of the Beatson Institute since 2002. Dr. Vousden is a fellow of the Royal Society, the Royal Society of Edinburgh, EMBO, the Academy of Medical Sciences, the European Academy of Sciences, and the American Association for the Advancement of Science. Her research focuses on the signals that induce tumour suppressor proteins and their function in cancer prevention and as a target for potential therapeutic development.

About Mitochondrial One-Carbon (1C) Metabolism

Targeting cellular metabolism is an increasingly important therapeutic approach for the treatment of people with cancer. In many types of cancer, the normal function of one-carbon (1C) metabolism is misregulated, driving tumor growth, proliferation and survival, primarily by supporting biomass accumulation. Breakthrough insights by Raze’s founders have identified 1C metabolic targets specific to certain tumors that, when selectively inhibited, stop the ability of tumors to accumulate biomass, offering the promise of targeted new cancer therapeutics.

About Raze Therapeutics

Raze Therapeutics is dedicated to the discovery and development of a new class of oncology therapeutics that target fundamental metabolic pathways essential to cancer growth and survival. By selectively targeting one-carbon (1C) metabolism using its proprietary platform, Raze is developing a pipeline of 1C metabolism therapeutics across a range of solid and hematologic cancers, including genetically-defined cancers. Raze is led by an experienced management team with a proven track record for building successful biotech companies and recognized scientific leaders in metabolism and cancer biology. The company was founded by Atlas Venture as a seed company and is funded by leading financial and corporate investors, including Atlas Venture, MPM Capital, MS Ventures, Partners Innovation Fund, Astellas Venture Management, and Novartis. For more information please visit the company’s website at: www.razetx.com or follow on Twitter at @RazeTx.

 

For information contact:

Feinstein Kean Healthcare
Jess Rowlands, (202) 729-4089
jessica.rowlands@fkhealth.com